The last 18 months have been the most consequential period in the history of peptide therapeutics regulation. The FDA has approved more peptide drugs for more indications than in any comparable period. Medicare announced it will cover GLP-1 drugs for weight loss for the first time. The agency cracked down on compounding pharmacies selling copycat semaglutide. And the new HHS Secretary, Robert F. Kennedy Jr., announced plans to reclassify ~14 peptides that the FDA had previously restricted from compounding.
These aren't isolated events. They represent a fundamental shift in how the US healthcare system treats peptides — from niche molecules used in diabetes management to a therapeutic class that may reshape how we treat obesity, liver disease, kidney disease, sleep apnea, and potentially aging itself.
This article covers every major FDA and US healthcare agency action on peptides from January 2025 through April 2026, identifies which specific peptides are involved, who benefits, and what it means for the future.
The Approvals: 2025–2026 Was a Historic Period
Orforglipron (Foundayo) — Eli Lilly | Approved April 1, 2026
The headline event. The FDA approved Eli Lilly's orforglipron (brand name Foundayo) as the first oral, non-peptide GLP-1 receptor agonist for adults with obesity or overweight with at least one weight-related comorbidity.
Why it matters:
- Record speed: Approved just 50 days after filing under the FDA's new Commissioner's National Priority Voucher (CNPV) pilot program — 294 days before its PDUFA target date. It was the fastest new molecular entity approval since 2002.
- No food restrictions: Unlike oral Wegovy (semaglutide), which requires a 30-minute fasting window, Foundayo can be taken with food. This is a major compliance advantage for real-world patients.
- Efficacy: The ATTAIN-1 trial showed 12.4% body weight reduction (27.3 lbs average) — less than injectable tirzepatide (~22%) but meaningful for a daily pill.
- Pricing: $25/month with a commercial insurance savings card; $149/month self-pay at the lowest dose. This is dramatically cheaper than injectable GLP-1s ($1,000+/month list price).
Who benefits: The ~100 million US adults with obesity or overweight. Patients who refuse or cannot tolerate injections now have a convenient daily pill option. Eli Lilly (LLY) gains a first-mover advantage in the oral non-peptide GLP-1 market worth an estimated $50B+ by 2030.
Oral Wegovy (Semaglutide 25 mg Pill) — Novo Nordisk | Approved December 2025
Novo Nordisk's answer to the oral GLP-1 race: a high-dose semaglutide pill approved for weight loss and cardiovascular risk reduction.
Key details:
- Efficacy: 16.6% body weight loss at 64 weeks in the OASIS 4 trial — comparable to injectable Wegovy and significantly more than orforglipron (12.4%)
- Limitation: Requires a 30-minute fasting window after ingestion (semaglutide is a peptide that degrades in the stomach without protection; orforglipron, being a small molecule, doesn't have this problem)
- Pricing: ~$149/month without insurance; ~$25 with insurance
- US launch began January 2026
Who benefits: Needle-phobic patients who want the full efficacy of semaglutide. Novo Nordisk (NVO) expands its total addressable market for the Wegovy franchise.
Wegovy for MASH — Novo Nordisk | Approved August 15, 2025
The FDA granted accelerated approval for semaglutide injection (2.4 mg) to treat noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis (F2-F3). This was the first GLP-1 receptor agonist approved for liver disease.
The data (ESSENCE trial):
- 63% of semaglutide patients achieved MASH resolution vs. 34% on placebo
- 36.8% achieved fibrosis improvement vs. 22.4% placebo
- 1,197 participants in a 240-week study
Who benefits: An estimated 6–8 million US adults with MASH and significant fibrosis — a population that previously had only one FDA-approved drug (Madrigal's resmetirom/Rezdiffra, approved March 2024). Novo Nordisk (NVO) now competes directly with Madrigal Pharmaceuticals (MDGL) in the MASH space.
Ozempic for Chronic Kidney Disease — Novo Nordisk | Approved January 28, 2025
The FDA approved semaglutide (Ozempic, 1 mg) to reduce the risk of worsening kidney disease, kidney failure (ESKD), and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD).
The data (FLOW trial):
- 24% relative risk reduction in the composite kidney endpoint
- Trial was stopped early for efficacy (3,533 adults across 28 countries)
- This made Ozempic the most broadly indicated GLP-1 RA on the market
Who benefits: ~37 million US adults have CKD; millions also have type 2 diabetes. This is a massive expansion of the semaglutide franchise into nephrology. Novo Nordisk (NVO) is the primary beneficiary; nephrologists now have a new tool backed by hard endpoint data.
Zepbound for Obstructive Sleep Apnea — Eli Lilly | Approved December 2024
Tirzepatide (Zepbound) became the first-ever medication approved specifically for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
The data (SURMOUNT-OSA):
- Reduced breathing interruptions by 25–29 events/hour
- Up to 50% of patients achieved remission or only mild OSA
- ~25 million US adults have OSA
Who benefits: OSA patients who currently rely solely on CPAP machines. Eli Lilly (LLY) adds another indication to the Zepbound franchise, strengthening its differentiation from semaglutide.
Elamipretide for Barth Syndrome — Stealth BioTherapeutics | Approved September 2025
A less-publicized but scientifically significant approval: elamipretide, a cell-permeable mitochondrial peptide, received accelerated approval as the first-ever treatment for Barth syndrome — a rare, life-threatening mitochondrial disease.
Why it matters for the peptide field:
- Validates mitochondrial peptide therapeutics as a viable drug class
- Demonstrates the FDA is willing to approve novel peptide mechanisms beyond GLP-1
- The TAZPOWER trial showed clinically meaningful improvement in cardiac and skeletal muscle function
Who benefits: ~150–200 US patients with Barth syndrome. More broadly, this paves the way for other mitochondrial peptides (including research peptides like MOTS-c and SS-31) to pursue regulatory approval.
Generic Liraglutide — Teva | Approved August 2025
The first-ever generic GLP-1 receptor agonist: Teva's generic liraglutide (bioequivalent to Saxenda) for weight management in adults and adolescents 12+ with obesity.
Pricing: ~$14,000/year wholesale acquisition cost (14% discount to branded Saxenda)
Who benefits: Cost-sensitive patients and payers. Teva Pharmaceutical (TEVA) gains a foothold in the GLP-1 market. Novo Nordisk faces its first generic competition in the GLP-1 weight loss space, though liraglutide (older generation, ~8% weight loss) is far less effective than semaglutide (~15-17%).
The Compounding Crackdown
While the FDA was approving new peptide drugs, it was simultaneously shutting down the massive market in compounded (non-FDA-approved) semaglutide and tirzepatide.
Timeline of Events
February 21, 2025: The FDA officially removed all doses of injectable semaglutide from the drug shortage list. Under federal law, pharmacies can only compound copies of FDA-approved drugs when those drugs are in shortage. Shortage resolution = compounding authority ends.
March 10, 2025: FDA published final enforcement guidance with grace periods:
- 503A pharmacies (traditional compounding): enforcement discretion ended April 22, 2025
- 503B outsourcing facilities (large-scale compounders): enforcement discretion ended May 22, 2025
April 24, 2025: A federal district court denied the Outsourcing Facilities Association's request for a preliminary injunction against the FDA's enforcement — a decisive legal victory for the agency.
September 9, 2025: The FDA sent 50+ warning letters to compounders and manufacturers targeting false claims that compounded products were "generic versions" or contained the "same active ingredient" as FDA-approved GLP-1s.
Who Lost, Who Won
Losers:
- Hims & Hers Health (HIMS) and other telehealth-compounding platforms face existential regulatory risk. Their compounded semaglutide and tirzepatide products — a major revenue driver — are under increasing enforcement pressure.
- Patients who relied on compounded GLP-1s for affordability ($200–400/month vs. $1,000+/month for branded) face difficult choices.
Winners:
- Novo Nordisk (NVO) benefits most, as patients shift back to branded Ozempic/Wegovy.
- Eli Lilly (LLY) benefits similarly for tirzepatide/Zepbound/Mounjaro.
- The approval of oral GLP-1s at $25–149/month partially addresses the affordability gap that drove compounding demand in the first place.
The RFK Jr. Peptide Reclassification: 14 Peptides May Return
This is the most politically charged development in peptide regulation — and the one most relevant to the longevity, biohacking, and functional medicine communities.
What Happened
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list would be moved back to Category 1 — making them available for compounding by pharmacies again.
The FDA's Category 2 list includes bulk drug substances the agency has identified as presenting "potential significant safety risks" when used in compounding. Being placed on Category 2 under the interim policies for Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act effectively prohibits pharmacies from compounding that substance.
The FDA's stated safety concerns are specific and documented. Here is the full Category 2 list of peptides, with the FDA's exact rationale for each:
The FDA Category 2 Peptide List (Official)
| Peptide | Section | Date Added | FDA's Stated Safety Concern |
|---|---|---|---|
| BPC-157 | 503A | Sep 29, 2023 | May pose risk for immunogenicity; complexities with peptide-related impurities and API characterization. FDA identified no or only limited safety-related information for the proposed routes of administration. |
| Cathelicidin LL-37 | 503A | Sep 29, 2023 | Risk for immunogenicity; peptide-related impurities. Nonclinical findings suggest detrimental effects on male reproduction and can be protumorigenic in some tissues. |
| Dihexa acetate | 503A | Sep 29, 2023 | FDA has not identified any human exposure data. Lacks information on whether it would cause harm if administered to humans. |
| Emideltide (DSIP) | 503A | Sep 29, 2023 | Immunogenicity risk; complexities with peptide-related impurities and API characterization. No safety-related information for proposed routes. |
| Epitalon | 503A | Sep 29, 2023 | Immunogenicity risk due to potential for aggregation and peptide-related impurities. No safety information for proposed routes. |
| GHK-Cu (injectable routes) | 503A | Sep 29, 2023 | Immunogenicity risk due to potential for aggregation and peptide-related impurities. Limited data in humans to inform safety considerations. |
| GHRP-2 (injectable and nasal) | 503B | Sep 29, 2023 | Immunogenicity risk; contains an unnatural amino acid complicating characterization. FDA aware of serious adverse events including death, increased insulin requirement, infection, and pancreatitis. |
| GHRP-6 | 503B | Sep 29, 2023 | Immunogenicity risk; limited safety-related information with safety concerns including potential effects on cortisol and blood glucose/insulin sensitivity. |
| Ibutamoren mesylate | 503A; 503B | Sep 29, 2023 / Dec 29, 2022 | Significant safety risks due to potential for congestive heart failure. A randomized trial in hip fracture patients was terminated early due to a safety signal of CHF. |
| Ipamorelin acetate | 503B | Sep 29, 2023 | Immunogenicity risk; contains unnatural amino acids. Published literature identified serious adverse events including death when administered IV for gastric motility. |
| Kisspeptin-10 | 503A | Sep 29, 2023 | Immunogenicity risk; complexities with peptide-related impurities. Limited safety information for proposed routes. |
Key pattern: The FDA's most common concern across these peptides is immunogenicity (the body mounting an immune reaction against the injected peptide), peptide-related impurities in compounded formulations, and a lack of human safety data for the routes of administration being used by compounding pharmacies.
Non-peptide substances also on Category 2 include cesium chloride (cardiac toxicity, added 2018), chloral hydrate (dosing errors/death, 503B, 2022), diethylstilbestrol (cancer risk, 503B, 2023), domperidone (cardiac arrhythmias/death, 2015), edetate disodium (interchange errors causing death, 503B, 2022), and germanium sesquioxide (kidney toxicity/death, 2016).
Which Peptides May Be Reclassified
Of these Category 2 peptides, RFK Jr.'s HHS announcement targets approximately 14 of 19 substances on the restricted list for reclassification back to Category 1. The peptides expected to move include:
| Peptide | Primary Therapeutic Use | Reclassification Status |
|---|---|---|
| BPC-157 | Gut healing, tissue repair, anti-inflammatory | 5 substances already removed from Category 2 |
| Epitalon | Telomerase activation, longevity research | Under PCAC review (July 24, 2026) |
| GHK-Cu | Skin regeneration, gene expression modulation | Expected reclassification |
| Ipamorelin | Growth hormone secretagogue, body composition | Expected reclassification |
| Emideltide (DSIP) | Sleep regulation, neuroprotection | Under PCAC review (July 24, 2026) |
| MOTS-c | Mitochondrial peptide, metabolic regulation | Under PCAC review (July 23, 2026) |
| KPV | Anti-inflammatory (alpha-MSH fragment) | Under PCAC review (July 23, 2026) |
| TB-500 (Thymosin Beta-4) | Tissue repair, wound healing, recovery | Under PCAC review (July 23, 2026) |
| Selank | Anxiolytic, cognitive enhancement | Expected reclassification |
| Semax | Neuroprotective, cognitive enhancement | Under PCAC review (July 24, 2026) |
| CJC-1295 | Growth hormone release | Expected reclassification |
| AOD-9604 | Fat metabolism (hGH fragment) | Expected reclassification |
PCAC Review Schedule
The FDA's Pharmacy Compounding Advisory Committee (PCAC) has scheduled formal reviews:
- July 23, 2026: BPC-157, KPV, TB-500, MOTS-c (for 503A Bulks List consideration)
- July 24, 2026: Emideltide (DSIP), Semax, Epitalon
- Before end of February 2027: Additional peptides to be reviewed
What This Means
If the reclassification goes through:
- Compounding pharmacies will legally be able to compound and sell these peptides again
- The functional medicine and longevity communities — which have been using these peptides extensively through gray-market channels — would gain legal, quality-controlled access
- Peptide supplier companies and compounding pharmacies would see significant revenue growth
Critical caveat: As of April 2026, the formal FDA rule change has not yet been published. Five peptides have already been removed from Category 2, but the remainder await PCAC review and formal rulemaking. The political will exists (Kennedy has been vocal), but the regulatory process takes time.
Who benefits:
- Compounding pharmacy stocks and private compounders
- Peptide raw material suppliers (e.g., Chinese API manufacturers, US-based peptide synthesis companies)
- Patients and practitioners in functional medicine, longevity, and sports recovery
- Potentially Stealth BioTherapeutics and other companies developing mitochondrial peptides (MOTS-c reclassification could validate the category)
The Medicare Breakthrough: CMS BALANCE Model
Perhaps the single largest market catalyst for the entire peptide therapeutics industry:
On December 23, 2025, CMS (Centers for Medicare & Medicaid Services) launched the BALANCE Model — a voluntary program to cover GLP-1 medications for weight management in Medicare Part D and Medicaid.
Timeline
| Milestone | Date |
|---|---|
| Medicaid coverage begins | May 2026 |
| Medicare GLP-1 Bridge starts ($50/month copay) | July 2026 |
| Full BALANCE Model (Medicare Part D) | January 2027 |
Why This Is Enormous
- Medicare covers ~67 million US beneficiaries
- Previously, Medicare Part D was statutorily prohibited from covering weight-loss drugs
- The BALANCE Model uses CMS authority to negotiate drug pricing directly with manufacturers
- At $50/month copay, this makes GLP-1s accessible to the population that needs them most — older adults with obesity-related comorbidities
Investment implication: This is the largest single policy catalyst for GLP-1 revenue growth in history. Every company with an approved GLP-1 benefits: Novo Nordisk (NVO), Eli Lilly (LLY), and eventually Teva (TEVA) with generic liraglutide.
Investment Landscape: Who Benefits Most
Tier 1: Clear Winners
| Company | Ticker | Key Catalyst | Why |
|---|---|---|---|
| Eli Lilly | LLY | Foundayo approval + retatrutide Phase 3 + Zepbound franchise | First oral non-peptide GLP-1; retatrutide showed 28.7% weight loss in TRIUMPH-4; OSA first-ever drug approval |
| Novo Nordisk | NVO | CagriSema NDA filed + oral Wegovy launch + MASH/CKD approvals | PDUFA ~October 2026; broadest approved indication portfolio; compounding crackdown redirects patients to branded products |
Tier 2: Significant Upside
| Company | Ticker | Key Catalyst | Why |
|---|---|---|---|
| Viking Therapeutics | VKTX | VK2735 Phase 3 enrollment complete | VANQUISH-1 + VANQUISH-2 fully enrolled; $706M cash; oral formulation Phase 3 planned Q3 2026; results ~late 2027 |
| Altimmune | ALT | Pemvidutide BTD for MASH | FDA Breakthrough Therapy Designation January 2026; differentiated dual GLP-1/glucagon mechanism; Phase 3 planned 2026 |
| Teva | TEVA | First generic GLP-1 | Generic liraglutide launched August 2025; lower-cost entry point to GLP-1 market |
Tier 3: Watch List
| Company | Ticker | Key Catalyst | Risk |
|---|---|---|---|
| Amgen | AMGN | MariTide (monthly dosing GLP-1) | Phase 2 data was mixed — 20% weight loss but Wall Street expected more; Phase 3 MARITIME enrolling |
| Structure Therapeutics | GPCR | Aleniglipron (oral small molecule GLP-1) | End-of-Phase-2 FDA meeting Q2 2026; Phase 3 H2 2026; lags behind orforglipron |
| Hims & Hers | HIMS | Compounding regulatory risk | Existential question: if FDA enforces compounding ban aggressively + RFK reclassification doesn't cover GLP-1s, the business model is under threat |
Key Losses
- Novo Nordisk's Alzheimer's program: The EVOKE and EVOKE+ trials of oral semaglutide for early Alzheimer's disease failed in November 2025, missing the primary endpoint. This eliminated a major potential $50B+ indication.
- Eli Lilly's tirzepatide HFpEF application: Withdrawn in May 2025 after the FDA requested an additional confirmatory trial. Novo's semaglutide HFpEF application (STEP-HFpEF data) remains under review.
The Pipeline: What's Coming Next
Retatrutide — Eli Lilly (Triple GIP/GLP-1/Glucagon Agonist)
The most anticipated peptide drug in development. Retatrutide is the world's first triple receptor agonist, activating GIP, GLP-1, and glucagon receptors simultaneously.
- TRIUMPH-4 Phase 3: 28.7% body weight loss at 68 weeks (December 2025) — the highest weight loss ever achieved in a large randomized trial
- TRANSCEND-T2D-1 Phase 3: Met all primary and secondary endpoints for type 2 diabetes (March 2026)
- Seven additional Phase 3 trials reading out through 2026
- NDA filing expected late 2026 or 2027
- If approved, retatrutide would likely become the most effective weight loss drug in history
CagriSema — Novo Nordisk (GLP-1 + Amylin Combo)
- NDA submitted December 18, 2025
- PDUFA target ~October 2026
- REDEFINE-1 showed 22.7% weight loss — below internal expectations but still superior to semaglutide alone
- If approved, first injectable GLP-1 + amylin analog combination
VK2735 — Viking Therapeutics (Dual GIP/GLP-1)
- Both Phase 3 trials (VANQUISH-1 and VANQUISH-2) fully enrolled as of March 2026
- ~4,650 patients in VANQUISH-1; additional patients in VANQUISH-2
- Oral formulation Phase 3 planned Q3 2026
- NDA/approval target ~2028
- $706 million cash position provides runway
What This Means for the Future
For Patients
The 2025–2026 regulatory actions mark a tipping point. GLP-1 drugs are no longer niche diabetes medications — they are becoming a standard-of-care intervention for obesity, MASH, CKD, OSA, and potentially heart failure. The approval of oral formulations (Foundayo, oral Wegovy) and Medicare coverage (BALANCE Model) removes the two biggest barriers to access: needles and cost.
For the longevity and functional medicine communities, the potential reclassification of research peptides like BPC-157, Thymosin Alpha-1, and MOTS-c could mark a shift from gray-market sourcing to legal, quality-controlled pharmacy compounding. But this depends on the PCAC reviews in July 2026 and subsequent rulemaking.
For Investors
The GLP-1 market is projected to exceed $150 billion annually by 2030. The key investment thesis has shifted from "will GLP-1s work?" (answered definitively) to "who captures market share in the oral/monthly/triple-agonist next generation?"
- Eli Lilly is positioning as the innovation leader (first oral non-peptide GLP-1, first triple agonist, first OSA drug)
- Novo Nordisk is the incumbent with the broadest indication portfolio (obesity, T2D, MASH, CKD, cardiovascular risk)
- Viking Therapeutics is the highest-upside speculative play with well-funded Phase 3 programs
- The compounding sector is a wild card: FDA enforcement pushes one way, RFK Jr. pushes the other
For the Peptide Field
These regulatory actions collectively signal that peptides have graduated from a research curiosity to a dominant therapeutic modality. The FDA's willingness to approve peptides for conditions far beyond diabetes — MASH, kidney disease, sleep apnea, Barth syndrome — expands the addressable disease space for the entire class.
The next frontier: peptides for aging itself. Life Biosciences' ER-100 (partial epigenetic reprogramming using Yamanaka factors) entered Phase 1 in January 2026. If the pattern of 2025–2026 continues — rapid approvals, expanded indications, Medicare coverage — the regulatory environment for longevity peptides may be more favorable than anyone expected.
Sources & Further Reading
- FDA Approves Lilly's Foundayo (Orforglipron) — April 1, 2026
- FDA Approves Oral Semaglutide for Weight Loss — December 2025
- FDA Approves Wegovy for MASH — August 15, 2025
- FDA Approves Ozempic for CKD — January 28, 2025
- FDA Approves Zepbound for OSA — December 20, 2024
- FDA Accelerated Approval of Elamipretide for Barth Syndrome — September 19, 2025
- CMS Launches BALANCE Model for GLP-1 Coverage — December 23, 2025
- FDA Sends 50+ Warning Letters to GLP-1 Compounders — September 2025
- FDA Peptide Reclassification — PBS — 2026
- PCAC Meeting Schedule — FDA — July 23-24, 2026
- Lilly's Retatrutide TRIUMPH-4 Phase 3 Results — December 2025
- Viking Therapeutics VANQUISH Enrollment Complete — March 2026
- Altimmune BTD for Pemvidutide — January 5, 2026
- Teva Generic Liraglutide Launch — August 28, 2025
- FDA. "Certain Bulk Drug Substances Used in Compounding." fda.gov/drugs/human-drug-compounding
Last updated: April 2026. This article is for educational purposes only and does not constitute investment advice.
